Article Text

Download PDFPDF
HLA-DQ2/DQ8 typing for non-biopsy diagnosis of coeliac disease: is it necessary?
  1. Siba Prosad Paul1,2,
  2. Jagrati Chopra2,3,
  3. Camelia Laura Vaina4,
  4. Akshatha Mallikarjuna2,
  5. Dharamveer Basude2,3
  1. 1 Paediatrics, Torbay Hospital, Torquay, UK
  2. 2 Paediatric Gastroenterology, Bristol Royal Hospital for Children, Bristol, UK
  3. 3 Medical School, University of Bristol Faculty of Health Sciences, Bristol, UK
  4. 4 Paediatrics, Yeovil District Hospital, Yeovil, UK
  1. Correspondence to Dr Siba Prosad Paul; siba.paul{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In 2012, the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) revised diagnostic guidance for paediatric coeliac disease (CD).1 It recommended a no-biopsy pathway (NBP) for symptomatic children if so-called ‘triple test’ criteria are satisfied1:

  • IgA anti-tissue transglutaminase antibodies (anti-tTGA) titre >10 times upper-limit-of-normal (10×ULN) and are IgA sufficient.

  • Positive IgA anti-endomysial antibodies (EMA).

  • Positive HLA-DQ2/DQ8 haplotype.

The British Society of Paediatric Gastroenterology, Hepatology and Nutrition adopted the guidelines in 2013. ESPGHAN suggested that CD can only be diagnosed by paediatric gastroenterologists or consultant paediatricians with special interest (SPIN) in gastroenterology.1 Many secondary care centres (SCC) in the UK have no SPIN consultant, therefore CD diagnosis is often made by (non-SPIN) general paediatricians.

The NBP was implemented in Southwest England (SWE) in May 2013.2 An electronic register is maintained in …

View Full Text


  • Contributors All authors contributed equally to the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Not required.